Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
- 19 April 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 16 (5) , 573-585
Abstract
Introduction: Immune check-point inhibitors are now employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC), while combinations of different inhibitors are being evaluated in clinical trials. Although the safety profile of these compounds, with particular reference to drugs targeting programmed death protein 1 (PD-1) and its ligand (PD-L1), is generally considered manageable, peculiar, immune-related toxicities may onset. Areas covered: This review focuses on the immune-related adverse events (irAEs) observed during immune check-point blockade in NSCLC and their management. The authors report the incidence of irAEs based on the currently available data involving NSCLC and provide recommendations on the general approach to irAEs, as well as indications for the most relevant site-specific events. Expert opinion: Since irAEs may involve a wide range of organs and systems and are potentially reversible if promptly treated, early diagnosis should always be achieved; this might be particularly challenging when other potential causes of toxicity are suspected, such as infections or concurrent treatments. Finally, drugs active on the PD-1/PD-L1 axis appear to be generally manageable even when they are administered to patients with relevant comorbidities, provided that adequate clinical monitoring is performed.Keywords
This publication has 90 references indexed in Scilit:
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancerOncoImmunology, 2016
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective studyThe Journal of Dermatology, 2016
- Checkpoint inhibitors in lung cancer: latest developments and clinical potentialTherapeutic Advances in Medical Oncology, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab TherapyJAMA Oncology, 2015
- Immune checkpoint inhibitors in advanced nonsmall cell lung cancerCurrent Opinion in Oncology, 2015
- Role of Immunotherapy in the Treatment of Advanced Non-Small-Cell Lung CancerFuture Oncology, 2013
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJournal of Leukocyte Biology, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012